A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

NCT00959699 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections
Hepatitis C
HCV Infection

Interventions

DRUG: PegIFN-2b
DRUG: RBV
DRUG: Placebo to Boceprevir
DRUG: Boceprevir

Sponsor

Merck Sharp & Dohme LLC